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The extracellular signal-regulated kinase (ERK) is one of the principal hub proteins that
transmit growth signals from upstream oncogene products including Ras and BRaf to down-
stream effector proteins. However, there are both reports supporting and refuting the
increase in ERK activity in cancer tissues expressing the active Ras and BRaf proteins. We
considered that the cell density might account for this discrepancy. To examine this possibil-
ity, we prepared Madin-Darby canine kidney (MDCK) cells that expressed an active HRas,
NRas, KRas, or BRaf and an ERK biosensor based on the principle of Fo¨rster resonance
energy transfer (FRET). As we anticipated, expression of the active Ras or BRaf increased
ERK activity at low cell densities. However, the ERK activity was markedly suppressed at
high cell densities irrespective of the expression of the active Ras or BRaf. Western blotting
analysis with Phos-tag gel revealed the decrease of tyrosine and threonine-diphosphory-
lated active ERK and the increase of tyrosine-monophosphorylated inactive ERK at high cell
density. In addition, we found that calyculin A, an inhibitor for PPP-subfamily protein serine/
threonine phosphatases, decreased the tyrosine-monophosphorylated ERK. Our study sug-
gests that PPP-subfamily phosphatases may be responsible for cell density-dependent
ERK dephosphorylation in cancer cells expressing active Ras or BRaf protein.
Introduction
Ras mutation is found up to 30% of human cancer patients [1]. Raf is one of the three major
effectors of Ras and is also mutated frequently in human cancers [2]. The extracellular signal-
regulated kinases (ERK1/2; MAPK3/1) are considered the canonical terminus of the Ras-Raf
branch, from which signals are dispatched to a number of proteins with different functions [3].
In agreement with these facts, an increase in phosphorylated active ERK (pERK) has been
reported in a number of cancer tissues [4,5]. However, there are also reports claiming that pERK
is not necessarily elevated in cancers harboring Ras and Raf mutations [6,7]. The failure to detect
elevated pERK in Ras- or Raf-transformed cells may be ascribable to adaptation to the constitu-
tively-active signals [8,9], or to technical pitfalls of immunohistochemistry [10]. It should also be
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recalled that many paradigms of oncogene signaling have been established by using rapidly-
growing tissue culture cells, which may be markedly different from cancer cells in patients.
One of the marked differences between in vitro and in vivo cellular milieus is cell density.
In contrast to tissue culture cells, which are often seeded at low cell densities to promote cellu-
lar replication, in vivo cancer cells grow mostly in a high cell density environment. It has been
well established that inhibition of cell proliferation occurs at high cell density; this phenome-
non is known as contact inhibition of cellular growth or simply contact inhibition [11,12]. In
non-transformed fibroblasts [13], epithelial cells [14], and vascular endothelial cells [15], cell-
to-cell contact causes downregulation of ERK and a subsequent decrease in cyclin D1. On the
other hand, the loss of contact inhibition is a hallmark of cancer cells in vitro [16]. Cells
infected by oncoretroviruses or transfected with oncogenes exhibit morphological changes
and uncontrolled cell growth even at high cell density [17–19]. Many oncogene products exert
their effect through activation of the Ras-Raf-ERK pathway; therefore, we can speculate that
constitutive activation of Ras or Raf and the resulting ERK activation may contribute to the
loss of contact inhibition of cancer cells. However, it has not been examined whether Ras or
Raf activation is sufficient to activate ERK at high cell density.
The development of biosensors based on Fo¨rster resonance energy transfer (FRET) has
opened a path to the analysis of cellular heterogeneity and temporal changes of the activities of
signaling molecules in vitro and in vivo [20,21]. For the measurement of ERK activity, we gen-
erated an intramolecular (unimolecular) FRET biosensor named EKAREV, which consists of a
donor fluorescent protein CFP, an ERK substrate peptide derived from Cdc25, an optimized
linker, a FHA1 phosphate binding domain, and an acceptor fluorescent protein YFP (Fig 1A)
[22,23]. Activated ERK phosphorylates the substrate peptide and induces intramolecular bind-
ing of the FHA1 domain to the phosphorylated peptide, thereby bringing the two fluorescent
proteins in close proximity to evoke FRET. The FRET biosensor is reversed to the pre-phos-
phorylation state by protein serine/threonine phosphatases (PSPs). The halflife of active ERK
is approximately 30 seconds, which is slow enough to be monitored by the FRET biosensors
[24]. Thus, by measuring the fluorescence intensities derived from FRET and CFP (FRET/CFP
ratio for brevity), we can obtain spatiotemporal information of the activity balance between
ERK and PSPs in living cells.
The EKAREV FRET biosensor has already been used in many studies. For example, we and
others have found that ERK can be stochastically activated in tissue culture cells [25,26], and
such stochastic ERK activation can be propagated to neighboring cells both in vitro and in
vivo [25,27]. Here, by using EKAREV, we examined the effects of oncogenic Ras and BRaf pro-
teins on ERK activity in Madin-Darby canine kidney (MDCK) cells cultured at high cell den-
sity. We found that, at high cell density, ERK activity was markedly decreased even in the Ras-
or BRaf-expressing MDCK cells. This suppression appears to be caused by the activation of
PSPs and resulting accumulation of inactive tyrosine-monophosphorylated ERK. Our observa-
tions imply that the discrepancy between the expression of active Ras or BRaf and ERK activity
in cancer tissues might reflect the difference in cell density-dependent activity of PSPs.
Materials and Methods
Plasmids and retroviruses
The nuclear FRET biosensor for ERK, EKAREV-NLS, was prepared as reported previously
[23]. Either Tol2 or piggyBac transposase was used for the stable expression of genes in
MDCK cells [28,29]. The coding sequence of EKAREV-NLS was inserted into
pT2AL200R175-CAGGS [29] to generate pT2A-3905NLS (pT2A-EKAREV-NLS).
pCAGGS-T2TP is an expression vector for the Tol2 transposase. pPBbsr2-lox-tdTomato-
Cell Density-Dependent Increase in Tyrosine-Monophosphorylated ERK2
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KRasV12 was based on pPBbsr2 [25,28] and comprised of a floxed tdTomato gene [30], a stop
codon, and a human KRasG12V gene in this order. pPBbsr2-lox-tdTomato-NRasV12,
HRasV12, and BRafV600E were generated by the standard PCR-based technology. pCMV-
mPBase (neo-) is an expression vector for piggyBac transposase. pCX4puro-ERT2CreERT2 is
derived from the pCX4puro retroviral expression plasmid [31] and comprised of ERT2CreERT2
[32]. The retroviral packaging plasmid pGP and the envelope plasmid
pCMV-VSV-G-RSV-Rev were used to generate recombinant retroviruses as described previ-
ously [33].
Establishment of MDCK cells expressing a FRET biosensor
MDCK cells were purchased from the RIKEN BioResource Center (no. RCB0995), and main-
tained in MEM (no. 51200038; Life Technologies, Carlsbad, CA) supplemented with 10% FBS
Fig 1. Establishment of MDCK cells expressing an active Ras or BRaf protein and a FRET biosensor
for ERK activity. (A) A scheme of the Ras-Raf-MEK-ERK pathway and the mode of action of the
intramolecular FRET biosensor, EKAREV-NLS. DUSPs, dual-specificity phosphatases; PSPs, protein serine/
threonine phosphatases. (B) Parental MDCK cells were stably-transfected with an expression vector for
EKAREV-NLS. The transfected cells were then further transfected with the pPBbsr2-lox-tdTomato-oncogene.
After the introduction of ERT2CreERT2, the oncogenes were induced by 4OHT. (C) The
MDCK-EKAREV-NLS-floxed-tdTomato-oncogene, the name of which is depicted in the first row, was cultured
in the presence or absence of 1 μM 4OHT and analyzed by Western blotting with the antibodies listed on the
left of each panel.
doi:10.1371/journal.pone.0167940.g001
Cell Density-Dependent Increase in Tyrosine-Monophosphorylated ERK2
PLOS ONE | DOI:10.1371/journal.pone.0167940 December 9, 2016 3 / 15
(Equitech-Bio, Woburn, MA), 1% non-essential amino acids (no. 11140050; Life Technology),
1% GlutaMAX Supplement (no. 35050061; Life Technology) and 1 mM sodium pyruvate (no.
11360070; Life Technology) in a 5% CO2 humidified incubator at 37˚C. To obtain MDCK-
EKAREV-NLS cells, MDCK cells were co-transfected with pT2A-EKAREV-NLS and
pCAGGS-T2TP and sorted by FACS as previously described [33]. MDCK-EKAREV-NLS cells
were co-transfected with pCMV-mPBase(neo-) and pPBbsr2-lox-tdTomato-HRasV12,
NRasV12, KRasV12, or -BrasV600E and selected by blasticidin S (no. 203350; Calbiochem,
San Diego, CA). These cells were infected with the retrovirus carrying the ERT2CreERT2 gene,
and selected by puromycin and sorted by FACS. After single cell cloning, the oncogenes were
induced by 1 μM tetrahydroxytamoxifen (4OHT; no. H7904; Sigma-Aldrich). After two-day
incubation, tdTomato-negative cells were used for further analyses.
Reagents and antibodies
Calyculin A (no. C5552) was purchased from Sigma-Aldrich (St. Louis, MO). Okadaic acid
was from Calbiochem (no. 459620). Phos-tag acrylamide AAL-107 (no. 304–93521) was pur-
chased from Wako Pure Chemical Industries, Ltd. (Osaka, Japan). The following antibodies
were purchased from Cell Signaling Technology (Danvers, MA): Anti-p44/42 MAPK (Erk1/2)
rabbit antibody (no. 4695), anti-phospho-p44/42 MAPK (Erk1/2) mouse antibody (no.
9106S), anti-S6 ribosomal protein rabbit antibody (no. 2317S), anti-phospho-S6 ribosomal
protein (Ser235/236) rabbit antibody (no. 4858S), anti-phospho-Akt (Ser473) mouse antibody
(no. 4060), anti-phospho-Akt (Thr308) rabbit antibody (no. 13038S), anti-pan Akt rabbit anti-
body (no. 4691S) and anti-β-actin rabbit antibody (no. 4790S). Anti-α-tubulin mouse antibody
was from Calbiochem (no. CP06). Odyssey Blocking Buffer (TBS) (no. 927–50000; LI-COR
Biosciences), IRDye680LT goat anti-rabbit IgG antibody (no. 925–68021) and IRDye800CW
donkey anti-mouse IgG antibody (no. 925–32212) were obtained from LI-COR Bioscience
(Lincoln, NE).
Polyacrylamide gel electrophoresis and Western blotting
Western blotting and Phos-tag polyacrylamide gel electrophoresis were performed essentially
as described previously [34]. Briefly, cells were lysed in SDS sample buffer [62.5 mM Tris-HCl
(pH 6.8), 12% glycerol, 2% SDS, 0.004% bromophenol blue and 5% 2-mercaptoethanol] at a
concentration of 430 cells/μL. After sonication and boiling at 95˚C, the samples were separated
by SDS-PAGE on SuperSep Ace 5–20% pre-cast gels (no. 197–15011; Wako Pure Chemical).
For Phos-tag Western blottings of ERK, 5.0 × 10−5 M Phos-tag Acrylamide (no. 304–93521;
Wako Pure Chemical) and 1.0 × 10−4 M MnCl2 (no. 21211; Nacalai tesque, Tokyo, Japan) were
added to conventional SDS-polyacrylamide separation gels according to the manufacturer’s
protocol. The samples were then transferred to PVDF membranes (no. IPFL00010; Merck
Millipore, Darmstadt, Germany). After 60-min of incubation with Odyssey blocking buffer
(TBS) at room temperature, the membranes were incubated overnight at 4˚C with primary
antibodies that were 1,000-fold diluted in Can Get Signal Immunoreaction Enhancer Solution
1 (no. NKB-201; TOYOBO, Osaka, Japan). The primary antibodies were visualized with fluo-
rescent Dye-tagged secondary antibodies that were 20,000-fold diluted in Odyssey blocking
buffer (TBS) and an Odyssey Infrared Imaging System (LI-COR).
Imaging
Live cell imaging was performed basically as previously reported [23,35]. In general, images of
MDCK cells expressing FRET biosensors were acquired every 5 to 10 min. After 30 min of
imaging under the pre-stimulation conditions, the cells were treated with reagents and further
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imaged for 60 min. For the wound-healing assay, Culture-Insert 2 Well™ (no. 81176; ibidi,
Martinsried, Germany) was used. Imaging was performed with an inverted microscope (IX83;
Olympus, Tokyo, Japan) equipped with 10× (NA 0.40), 20× (NA 0.75) and 40× (NA 0.95)
objective lenses (UPlan SApo; Olympus), a cooled CCD camera (Cool SNAP-K4; Roper Scien-
tific), an LED illumination system (CoolLED precisExcite; Molecular Devices), an IX2-ZDC
laser-based autofocusing system (Olympus) and a D-XY30100T-Meta automatically program-
mable XY stage (SIGMA KOKI, Tokyo, Japan). The following filters used for the dual emission
imaging studies were obtained from Omega Optical (Brattleboro, VT): an XF1071 (440AF21)
excitation filter, an XF2034 (455DRLP) dichroic mirror, and three emission filters (FF01-483/
32-25 for CFP, FF01-542/27-25 for FRET and YFP, and FF01-593/40-25 for tdTomato).
Image processing
Metamorph software (Molecular Devices, Sunnyvale, CA) was used for background noise sub-
traction and image analysis. Background intensities were determined by using an empty cul-
ture dish with the same amount of media. After background subtraction, the FRET/CFP ratio
images were represented in the intensity-modulated display (IMD) mode. In the IMD mode,
eight colors from red to blue are used to represent the FRET/CFP ratio, with the intensity of
each color indicating the mean intensity of FRET and CFP channels. Heatmap images repre-
senting the relationship between the FRET/CFP ratio and time course were generated using
MATLAB software (MathWorks, Natick, MA).
Statistics
Statistical analyses were conducted using R software (ver. 3.1.3). In the beeswarm plot, a bold
line indicates the median, and fine lines, if any, denote the upper and lower quantiles, respec-
tively. To compare two sets of data, Student’s t test or Welch’s t test was performed according
to a result of F test. As a multiple comparison test, Tukey’s honestly significant difference test
or Steel-Dwass test was used after validation of homoscedasticity by Bartlett’s test. In all tests,
values of p< 0.05 were considered significant.
Results
Establishment of MDCK cells expressing an active Ras or BRaf protein
and a FRET biosensor for ERK activity
For the measurement of ERK activity in living cells, a FRET biosensor for ERK, EKAR-
EV-NLS, was expressed in the nucleus of MDCK cells. The 4OHT-inducible Cre-dependent
expression system was employed to minimize the inter-clonal variation (Fig 1A and 1B).
Active mutants of four oncogene products, HRasG12V, NRasG12V, KRasG12V, and
BRafV600E, were designed to be expressed in MDCK cells. Induction of each oncogene prod-
uct was indeed confirmed by Western blotting analysis (Fig 1C).
Cell density-dependent suppression of ERK activity in MDCK cells
expressing an active Ras or BRaf protein
To examine the effect of the cell density on ERK activity, we first plated the MDCK-EKAR-
EV-NLS cells without induction of oncogene at increasing cell densities. In FRET/CFP ratio
images acquired before induction of NRasG12V, as reported previously [25,26], ERK activity
was heterogeneous at low cell density (Fig 2A). A timelapse video and a heatmap of other pre-
induction cell line, MDCK-EKAREV-NLS-floxed-tdTomato-KRasG12V cells, also showed
this heterogeneity and it was generated by stochastic ERK activity pulses (Fig 2B left).
Cell Density-Dependent Increase in Tyrosine-Monophosphorylated ERK2
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However, at high cell density, both the basal ERK activity and the stochastic ERK activity pulse
were suppressed (Fig 2B right, S1 Movie). We next induced KRasG12V by 4OHT and analyzed
their activities at low and high cell densities (Fig 2C, S2 Movie). At low cell density, KRasG12V
cells induced robust ERK activation and abolished ERK activity pulses (Fig 2C left). However,
ERK activity was markedly suppressed to a level comparable to that of the pre-induced cells at
high cell density (Fig 2C right). We also analyzed other MDCK cell lines that encoded
HRasG12V, NRasG12V, and BRafV600E about ERK activity at different cell densities and the
expression of oncogenic mutants. Again, the cells were plated at low and high cell densities
and examined for ERK activity (Fig 2D). The beeswarm plots confirmed that the induction of
oncogene products raised the ERK activity at low cell density, but that the oncogene products-
induced high ERK activation could be antagonized by high cell density. These observations
clearly indicate that the high ERK activity induced by active oncogene products is subject to
the suppression by high cell density.
ERK activity change in the wound-healing assay
The low ERK activity at high cell density suggests the two following possibilities. First, low cell
density, i.e., a large cell-to-substratum area, may be required for the induction of high ERK
activity by oncogene products. Second, a free edge, i.e., a plasma membrane that does not face
the other cells, may be required for ERK activation by the oncogene products. In support of
the latter view, it has been proposed that Ras is activated at the free edge but not at the plasma
membrane facing the neighboring cells [36]. To resolve this question, we performed a wound
healing assay. MDCK cells expressing NRasG12V were plated on two chambers separated by a
silicon wall, which could be removed during the experiment. No difference in ERK activity
was found whether or not the cells were facing the silicon wall (Fig 3A). Upon removal of the
silicon wall, the cells that had faced the silicon wall moved forward and exhibited a rapid
increase in ERK activity, even though these cells were still in contact with the follower cells
(Fig 3B and 3C). When the cells of both edges filled the gap, ERK activity was decreased gradu-
ally. In the leading cells that faced to the silicon insert, the length of the cell border in contact
with the other cells did not change significantly during cell migration. Therefore, the high cell
density, but not the cell-to-cell contact, appears to suppress ERK activity in
MDCK-NRasG12V cells cultured at high cell density.
Accumulation of tyrosine-monophosphorylated inactive ERK at high cell
density
How can ERK activity be suppressed in MDCK cells expressing the active Ras or BRaf? To
answer this question, we examined the phosphorylation status of ERK by using Phos-tag gels
as described previously [34]. ERK has four distinct forms according to the phosphorylation
status of tyrosine and threonine residues within the catalytic loop (Fig 4A). Non-phosphory-
lated ERK (np-ERK) is first phosphorylated on tyrosine to generate tyrosine-monopho-
sphorylated ERK (pY-ERK). pY-ERK is then further phosphorylated to generate tyrosine
and threonine diphosphorylated ERK (pTpY-ERK), which is the enzymatically-active form.
Dephosphorylation can follow two pathways via either pY-ERK or threonine-monopho-
sphorylated ERK (pT-ERK). These four states of ERK could be separated by Phos-tag gels
and probed with an anti-ERK antibody (Fig 4B). Because ERK2 is significantly more abun-
dant than ERK1, we concentrated our efforts on quantification of the amount of ERK2 phos-
pho-isoforms in MDCK cells with or without HRasG12V expression (Fig 4C). As was
anticipated from the imaging data, the amount of pTpY-ERK was increased by the induction
of HRasG12V and correlated inversely with the cell density. Notably, this decrease in
Cell Density-Dependent Increase in Tyrosine-Monophosphorylated ERK2
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Fig 2. Cell density-dependent suppression of ERK activity in MDCK cells expressing an active Ras or BRaf. (A) MDCK-floxed-tdTomato-
NRasG12V cells before 4OHT induction were plated at the cell densities depicted at the bottom of each panel and imaged with a fluorescence
microscope. FRET/CFP ratio images in the intensity-modulated display mode indicate the ERK activity. Bars, 50 μm. (B) MDCK-floxed-tdTomato-
KRasG12V cells were time-lapse imaged for 450 min. The mean FRET/CFP ratios at low cell density (0.5×104 cells/cm2) and at high cell density (4×104
cells/cm2) are shown by heatmaps. Each row represents time course of FRET/CFP ratio of single cell. The numbers of analyzed cells are 5 for low cell
density and 150 for high cell density. (C) Similar experiments were performed after 4OHT induction. (D) MDCK-floxed-tdTomato-oncogene cells before
and after 4OHT induction were plated at low and high cell densities and imaged with a fluorescent microscope. The FRET/CFP ratios of 90 cells from
three independent experiments are plotted for each condition.
doi:10.1371/journal.pone.0167940.g002
Cell Density-Dependent Increase in Tyrosine-Monophosphorylated ERK2
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pTpY-ERK at high cell density was accompanied by the increase in pY-ERK. Meanwhile, np-
ERK was not significantly changed by the difference of cell density. Similar results were
obtained by using MDCK cells expressing NRasG12V, KRasG12V, or BRafV600E (Fig 4D).
Taken together, our observations raised the possibility that serine/threonine phosphatases
were activated to invoke the shift from pTpY-ERK2 to pY-ERK2 under the high cell density
condition (Fig 4E).
Recently, Iwamoto et al. reported that pTpY-ERK and pT-ERK, but not pY-ERK, are
increased in the Ras-transformed keratinocyte cell line HaCaT A5 [37]. In this cell line,
DUSP6 has been shown to contribute to the accumulation of pT-ERK. The cause of the dis-
crepancy may be the difference of cell type.
Decreased phosphorylation of Akt and S6 ribosomal protein at high cell
density
If serine/threonine phosphatase activity was increased at high cell density, decreased phos-
phorylation would be observed not only in ERK2 but also other downstream effector pro-
teins of Ras. To examine whether this is the case, the phosphorylations of Akt and its
downstream effector S6 ribosomal protein were examined by Western blotting (Fig 5). Upon
induction of KRasG12V, phosphorylations of Akt and the S6 protein were increased at low
cell density. This increase in phosphorylation was attenuated at high cell density (A and C).
Upon the induction of BRafV600E, neither phosphorylation of Akt nor that of the S6 ribo-
somal protein was increased, which may suggest negative regulation at the level of Ras (B
and D). Nevertheless, the phosphorylations of Akt and the S6 ribosomal protein were
decreased at high cell density, implying that serine/threonine phosphatase activity was
increased at high cell density.
Fig 3. ERK activity change in the wound-healing assay. (A) MDCK cells expressing NRasG12V and
EKAREV-NLS were plated in Culture-Insert 2 Well (ibidi) at high cell density and imaged with a fluorescence
microscope. No difference in ERK activity was detected between cells in contact with and cells apart from the
silicon insert. Bar, 200 μm. (B and C) The wound-healing assay was started by removing the silicon insert.
Representative consecutive FRET/CFP ratio images. Bar, 50 μm (B). The FRET/CFP ratios in 14 cells at the
border were monitored and plotted over time. Mean ± SD (C).
doi:10.1371/journal.pone.0167940.g003
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Decreased pY-ERK2 in calyculin A-treated MDCK cells at high cell
density
To gain further insight into the nature of phosphatases upregulated in confluent MDCK cells,
we used inhibitors of PSPs. PSPs comprise three major families: phosphoprotein phosphatases
Fig 4. Increase in tyrosine-monophosphorylated ERK at high cell density. (A) A schematic representation of the ERK phosphorylation status.
np-ERK2, non-phosphorylated ERK2; pT-ERK2, ERK2 monophosphorylated on Thr185; pY-ERK2, ERK2 monophosphorylated on Tyr187;
pTpY-ERK2, ERK2 diphosphorylated on Thr185 and Tyr187; DUSPs, dual specificity phosphatases; PSPs, protein serine/threonine phosphatases. (B)
MDCK-floxed-tdTomato-HRasG12V cells before and after 4OHT induction were plated at the cell densities depicted at the bottom of each lane and
analyzed by Western blotting analysis with Phos-tag gels. The filters were probed with anti-ERK and anti-phospho-ERK (Thr185/Tyr187) antibodies.
The yellow bands indicate pTpY-ERK1 and pTpY-ERK2. (C) The fluorescence intensities of ERK2 proteins were quantified and the percentage of
each phospho-isoform is plotted. Data obtained from three independent experiments are shown. *p < 0.05. (D) Similar experiments were performed
with MDCK cells before and after the induction of NRasG12V, KRasG12V, or BRafV600E as indicated. Data are shown only for pY-ERK2 and
pTpY-ERK2 for simplicity. *p < 0.05; **p < 0.01. (E) A schematic of the mechanism of decrease in pTpY-ERK2 at high cell density.
doi:10.1371/journal.pone.0167940.g004
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(PPPs), metal-dependent protein phosphatases (PPMs), and the aspartate-based phosphatases
[38,39]. The largest PPP-family proteins include PP1 and PP2A, which are ubiquitously
expressed. Calyculin A inhibits a broad range of both PP2A and PP1. Okadaic acid inhibits
PP2A completely, but inhibits PP1 only partially at the concentrations used in this study
[40,41]. Neither of them inhibits PPMs or the aspartate-based phosphatases [42].
MCDK-HRasG12V cells plated at low and high cell densities were treated with calyculin A
and okadaic acid and examined for ERK activity by FRET imaging (Fig 6A and 6B). Calyculin
A, but not okadaic acid, was found to increase the ERK activity, suggesting that PP1 is
Fig 5. Cell density-dependent decrease of phosphorylation of Akt and S6 ribosomal protein. (A and B) MDCK cells before and after
KRasG12V or BRafV600E induction were plated at the cell densities depicted at the bottom of each column and analyzed by Western blotting with
anti-Akt, anti-phospho-Akt (Thr308), anti-phospho-Akt (Ser473), anti-S6 ribosomal protein antibody, and anti-phospho-S6 ribosomal protein
(Ser235/236). (C and D) Quantification of each band in the blotting. Y-axis represents fold change comparing with the pre-induction cells at the low
cell density as control.
doi:10.1371/journal.pone.0167940.g005
Cell Density-Dependent Increase in Tyrosine-Monophosphorylated ERK2
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responsible for the confluency-dependent suppression of ERK. To further confirm the effect of
calyculin A, the phosphorylation status of ERK was examined by Western blotting with Phos-
tag gels. In agreement with the imaging data, calyculin A was found to decrease np-ERK2 and
to increase pTpY-ERK2 at all cell densities (Fig 6C and 6D). Importantly, calyculin A
decreased pY-ERK2 at high cell density in MDCK cells expressing HRasG12V, which supports
the findings shown in Fig 3 that accumulation of pY-ERK was the primary cause of ERK sup-
pression at high cell density.
Fig 6. Calyculin A-induced decrease of tyrosine-monophosphorylated ERK2 at high cell density. (A and B) MDCK cells were stimulated with 5
nM calyculin A (A) or 500 nM okadaic acid (B). The mean and upper/lower quantiles of FRET/CFP ratios are plotted before and after 30 min incubation,
respectively (n = 50). *p < 0.05; **p < 0.01. (C) Cells were plated at the indicated cell density, cultured overnight, and incubated with 5 nM calyculin A
for 30 minutes, followed by Phos-tag Western blot analysis with anti-ERK and anti-phospho-ERK (Thr185/Tyr187) antibodies as shown in Fig 4. (D) The
difference between the fractions of calyculin A-treated cells (C) and non-treated cells (Fig 4C) is shown.
doi:10.1371/journal.pone.0167940.g006
Cell Density-Dependent Increase in Tyrosine-Monophosphorylated ERK2
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Discussion
The loss of contact inhibition is a hallmark of cancer cells in vitro [19]. In earlier studies,
expression of active oncogenes was believed to be sufficient to induce contact inhibition; how-
ever, later studies have shown that additional mutations endow robust malignant features
[43,44]. In agreement, we have also found that expression of Ras or BRaf was not sufficient to
override the cell density-dependent suppression of ERK2 activity. We have further shown that
the suppression of ERK activity was caused primarily by the transition of the active
pTpY-ERK2 to inactive pY-ERK2. The sensitivity to calyculin A, but not to okadaic acid, sug-
gests the involvement of PP1 in the cell density-dependent suppression of ERK2.
Dephosphorylation is the reverse reaction of protein phosphorylation and should play
important roles in the regulation of cancer cell growth. Nevertheless, the number of PSPs are
markedly less than that of protein kinases, implying that PSPs revert broad spectrum of protein
kinase reactions, each of which is dictated by a specific protein kinase(s) [39]. In contrast to
the pro-oncogenic roles played by protein kinases, PSPs are generally regarded as the tumor
suppressor. For example, PP2A is known to regulate cell cycle and apoptosis of cancer cells.
Furthermore, recent preclinical studies have shown that PP2A-activating drugs can antagonize
cancer development and progression [45]. Similarly to PP2A, PP1 regulates a number of bio-
logical phenomena including cell division, apoptosis, metabolism, protein synthesis, regulation
of cytoskeleton and ion receptors [46]. Due to the pleiotropic functions of PP1, there are some
discrepancies on the mechanism by which PP1 regulates ERK. PP1 dephosphorylates phos-
pho-Ser259 of CRaf, which binds to 14-3-3 and thereby suppresses kinase activity. Conse-
quently, PP1 activates ERK via CRaf activation [47,48]. On the other hand, PP1 has been
shown to negatively control ERK via DARPP-32 protein in a subset of medium-size spiny neu-
rons of the dorsal striatum and nucleus accumbens [49]. We suggest that PP1 negatively regu-
lates ERK activity via dephosphorylation of threonine (Fig 4) in a cell density dependent
manner. Therefore, the action of PP1 on the Ras-Raf-ERK pathway appears to be dependent
on not only the cell types but also the cell density. It should also be mentioned that the discrep-
ancy between the expression of active Ras or BRaf and ERK activity in cancer tissues may be
ascribable to the activity of PP1 in each cancer tissue.
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